Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly
inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and
improving ventricular compliance. This is an open-label, parallel-group, single-center Phase
1 clinical study. Healthy adult Chinese subjects with different CYP2C19 genotypes (Cohort 1
and Cohort 2: CYP2C19 UM, RM, or NM; Cohort 3: CYP2C19 IM; Cohort 4: CYP2C19 PM) will be
included and administered with a single fasted oral dose of mavacamten to evaluate its PK
profile. Up to 44 subjects will be enrolled in this study.